Wegovy Price in UAE: Cost & Dosing Guide

What Does Wegovy Cost in the UAE?

At UAE pharmacies, Wegovy’s monthly cost for the 2.4 mg maintenance dose is typically reported around AED 1,200 to AED 1,500. Individual Wegovy injection pens may appear across a wider AED range by strength and source, with lower titration doses (0.25–1.0 mg) often listed around AED 700–800 and some higher-strength or bundled listings reaching above AED 1,700. Clinic-administered programmes that include physician consultations, blood work, and follow-up monitoring typically quote AED 1,800–3,000 per month. Treat these as indicative ranges that vary by pharmacy, clinic, dose, stock state, and date checked — across published guides the all-in Wegovy figure spans roughly AED 1,199–3,000/month. This is why searches for wegovy price uae, wegovy uae price, wegovy price in Dubai, wegovy Dubai, and semaglutide UAE can return different figures or mixed Wegovy/Ozempic results.

Wegovy UAE Pharmacy Availability

Major UAE pharmacy chains carrying Wegovy include BinSina Pharmacy, Life Pharmacy, and myAster when stock is available. A valid prescription from a licensed physician is required, and pharmacies verify prescriber credentials, dose strength, and dispensing details before fulfilment. For a broader UAE access table across Wegovy, Ozempic, Mounjaro, Rybelsus, Saxenda, and Foundayo, see our GLP-1 medications UAE availability and cost guide.

Insurance Coverage and Self Pay

Most UAE insurance plans regulated by DHA (Dubai) and DOH (Abu Dhabi) do not cover Wegovy. Weight-management medicines are often classified outside standard benefits, so self-pay pricing is common in Dubai and the wider UAE. In the US, coverage is more nuanced: some commercial plans cover Wegovy under weight-management medicine benefits, while many employer plans exclude it.

Savings Offers and NovoCare Pharmacy Support

In the US market, Novo Nordisk offers a savings offer through NovoCare pharmacy support that can provide maximum savings of up to $500 per month on eligible prescriptions. No comparable UAE-wide savings offer is published. UAE pharmacy loyalty programmes or temporary discounts, where available, should be checked directly against current listings rather than assumed from US NovoCare terms.

How UAE Pricing Compares Globally

UAE pricing (AED 1,200–1,500/month, approximately $326–$408) sits below the US list price of approximately $1,349 per month, comparable to Germany (EUR 172–328/month depending on dose), and significantly above UK NHS access where eligible users pay only a GBP 9.90 prescription charge. Unlike the UK, no broad subsidised pricing pathway exists in the UAE, so Wegovy cost in Dubai and Abu Dhabi depends heavily on the pharmacy or clinic route.

The 5-Step Titration Schedule

The label-based Wegovy dosing schedule uses a standardised 16-week dose escalation before the 2.4 mg maintenance strength. Each titration step lasts four weeks. The rationale in prescribing information is gradual GLP-1 receptor activation and improved gastrointestinal tolerability; this table is provided for research and market context, not personalised dosing advice.

Prescribing information describes dose-delay options when tolerability limits escalation and notes that 1.7 mg may be used when the 2.4 mg maintenance strength is not tolerated. Any clinical decision belongs with a licensed prescriber; this guide is limited to label and research-data interpretation.

STEP Trial Efficacy Data

The STEP (Semaglutide Treatment Effect in People with Obesity) programme is the largest clinical trial programme conducted for a weight-management GLP-1 drug. Five pivotal trials enrolled over 4,500 participants across multiple populations and treatment durations. For molecule-level background, see our semaglutide profile.

STEP 1: The Landmark Trial

Published in the New England Journal of Medicine (2021), STEP 1 randomised 1,961 adults with obesity (BMI ≥30 or ≥27 with comorbidities) to semaglutide 2.4 mg or placebo for 68 weeks. The results were definitive:

• Mean weight loss: −14.9% with semaglutide vs −2.4% placebo
• 86.4% achieved ≥5% weight loss (vs 31.5% placebo)
• 69.1% achieved ≥10% weight loss (vs 12.0% placebo)
• 50.5% achieved ≥15% weight loss (vs 4.9% placebo)

Across the STEP Programme

• STEP 2 (type 2 diabetes): −9.6% weight loss—lower than STEP 1, as expected in diabetic populations
• STEP 3 (intensive behavioural therapy): −16.0% weight loss when combined with low-calorie diet
• STEP 4 (continuation vs withdrawal): −17.4% maintained with ongoing semaglutide; participants switched to placebo regained weight
• STEP 5 (2-year data): −15.2% sustained at 104 weeks, confirming long-term durability

Across all STEP trials, semaglutide 2.4 mg consistently delivered 14.9–17.4% body weight reduction in non-diabetic populations, with simultaneous improvements in waist circumference, blood pressure, lipid profiles, and C-reactive protein.

Side Effects by Dose Tier

Gastrointestinal adverse events are the primary side effect of Wegovy, and they follow a predictable pattern tied to dose escalation. Across the STEP programme, cumulative rates for semaglutide 2.4 mg versus placebo were:

• Nausea: 43.9% vs 16.1%
• Diarrhoea: 29.7% vs 15.9%
• Vomiting: 24.5% vs 6.3%
• Constipation: 24.2% vs 11.1%

The critical nuance: 99.5% of GI events were non-serious and 98.1% were mild to moderate. The cumulative incidence of first GI adverse events plateaued after week 20, meaning nearly all side effects appeared during the titration window and improved over time in trial reporting. Only 4.1% of semaglutide participants experienced severe GI events.

This is the tolerability rationale behind the 16-week titration schedule in the label. Trial and prescribing-information data associate faster escalation with higher nausea and vomiting rates, while gradual escalation allows gastrointestinal adaptation to GLP-1 receptor activation. For further comparison of GI side effects across GLP-1 drugs, see our side effects comparison.

Other Common Side Effects

Beyond nausea and diarrhoea, prescribing information and STEP trial reports include upset stomach, feeling bloated, gastroenteritis, slowed gastric emptying, upper respiratory symptoms, dizziness, hair-loss reports associated with rapid weight change, and rare trouble swallowing. Serious-symptom handling is outside this article’s scope; readers should rely on product labeling and licensed clinical advice for medical decisions.

Serious Side Effects and Boxed Warnings

Wegovy carries a boxed warning regarding thyroid tumors. In animal studies, semaglutide caused thyroid tumors including medullary thyroid carcinoma in rodents. The label lists personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 as a contraindication. Other serious risks in labeling include pancreatitis, gallbladder problems, low blood sugar (hypoglycaemia, especially with insulin or sulfonylureas), kidney injury, and increased heart rate.

Cardiovascular Safety: The SELECT Trial

The SELECT trial reported a 20% reduction in major cardiovascular events, including heart attack, stroke, and cardiovascular death, in adults with known heart disease and either obesity or overweight. This was the first time a weight-management medicine demonstrated major adverse cardiovascular event reduction in this setting. The FDA updated Wegovy’s label in March 2024 to include cardiovascular risk reduction as an indication.

Pen Specifications & Storage

In the UAE and Europe, Wegovy is supplied as FlexTouch multi-dose pre filled pens. Each Wegovy pen contains four weekly doses, and each dose strength has a dedicated pen format. These specifications help explain why Wegovy injection price in UAE varies by strength and why pharmacy listings often separate 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg products.

Label Administration Context

The prescribing information describes Wegovy as a subcutaneous injection product with dose-specific pen strengths and separate storage requirements. This article does not provide injection technique, missed-dose instructions, or personal dosing guidance; those details belong in official labeling and licensed clinical care.

Storage Requirements

• Before first use: Refrigerated at 2–8°C (36–46°F)
• After first use: Room temperature (up to 30°C / 86°F) for a maximum of 28 days, according to labeling
• Keep in original carton to protect from light
• Do not freeze—discard if frozen
• Once removed from refrigeration, the 28-day window cannot be reset by re-refrigerating

Shelf life is 24 months when stored properly under refrigeration. For a broader overview of peptide storage principles, see our stability and storage guide.

Diet and Activity Context in STEP Trials

Wegovy trial outcomes are not medication-only figures. The STEP trials included reduced-calorie diet and increased physical activity interventions, which is why the published data should be read as combined intervention outcomes rather than isolated drug-effect estimates.

Nutritional Context

STEP protocols used reduced-calorie diet targets and lifestyle support. Because GLP-1 receptor agonists affect appetite and gastric emptying, trial interpretation often discusses food intake, protein intake, lean mass preservation, and diet quality. These points explain the study design; they are not individualized nutrition advice.

Activity and Blood Sugar Context

The STEP programme also included activity guidance and metabolic monitoring. In participants with type 2 diabetes, blood sugar context matters because concomitant insulin or sulfonylureas can affect hypoglycaemia risk. For broader comparison across injectable options in Dubai, see our weight loss injections Dubai price guide.

Wegovy vs Ozempic: Same Molecule, Different Drug

Wegovy and Ozempic are both semaglutide manufactured by Novo Nordisk. The critical differences are regulatory indication, dosing ceiling, and titration protocol.

• Indication: Wegovy is approved specifically for chronic weight management. Ozempic is approved for type 2 diabetes and cardiovascular risk reduction. Off-label Ozempic use for weight loss is common in market reporting.
• Maximum dose: Wegovy reaches 2.4 mg/week through 5 titration steps. Ozempic caps at 2.0 mg/week, with 1.0 mg commonly referenced in prescribing and pharmacy contexts.
• Titration: Wegovy’s 5-step protocol takes 16 weeks. Ozempic has a simpler 3-step escalation (0.25 → 0.5 → 1.0 mg, with optional 2.0 mg).
• Pen format: Both use FlexTouch pens in the UAE, but Wegovy pens are dose-specific while Ozempic pens allow multi-dose dialling.

In May 2024, Novo Nordisk publicly urged UAE users of off-label Ozempic for weight loss to switch to Wegovy, the medicine with the weight-management indication, to reduce pressure on Ozempic supply for diabetes care. The higher semaglutide dose in Wegovy (2.4 mg vs 1.0–2.0 mg) also aligns with the larger weight-loss effect reported in STEP trials. For a detailed comparison of liraglutide versus semaglutide, see our Saxenda vs Ozempic analysis.

The Wegovy Pill: Oral Semaglutide for Weight Loss

On December 22, 2025, the FDA approved the oral Wegovy pill (oral semaglutide 25 mg) — the first oral GLP-1 approved for adult weight management in the US. The oral formulation uses the same active ingredient (semaglutide) with the SNAC absorption enhancer. Reported mean weight loss is ~17% (treatment-policy estimand) and 16.6% in the EU CHMP filing.

The oral semaglutide label describes specific fasting and water-volume administration conditions. On May 22, 2026, the EMA Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the Wegovy pill for EU weight management. The oral version is not yet approved in the UAE; UAE availability historically follows the EU lead, so searches for wegovy pill UAE currently point to pipeline and regulatory-status context rather than UAE pharmacy access.

Wegovy 7.2 mg Single-Dose Pen — A Higher-Dose Tier on the Horizon

On the same day (May 22, 2026), CHMP also issued a positive opinion on the Wegovy 7.2 mg single-dose pen, a higher-dose injectable Wegovy reporting up to 20.7% mean weight loss — the highest figure across the semaglutide family. EU launch is expected in 2026. UAE availability has not been announced; the UAE historically follows EU approvals, so the 7.2 mg pen is a horizon item to track rather than a current option. Until then, the UAE injectable line remains 0.25 mg → 2.4 mg, and the AED 1,200–1,500/month maintenance pricing in this guide reflects the 2.4 mg pen.

Foundayo (orforglipron) — Eli Lilly’s once-daily oral non-peptide GLP-1 agonist — was FDA-approved on April 1, 2026 and approved by the Emirates Drug Establishment in early April 2026, with UAE availability from May 2026. Unlike the Wegovy pill, Foundayo labeling has no food, water, or timing restrictions. ATTAIN-1 reported ~12.4% mean weight loss at 72 weeks at the FDA-approved 17.2 mg dose. For a broader overview of emerging oral obesity drugs, see our oral obesity drug pipeline analysis.

On the supply side, the US compounded-semaglutide route is closing. In a Federal Register notice dated May 1, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, citing no clinical need now that the branded products are off the shortage list. For UAE readers, the practical distinction is clear: licensed pharmacy access to approved Wegovy products is not equivalent to informal or compounded semaglutide supply. UAE law (MoHAP) is unchanged by this US move.

How Does Retatrutide Compare?

Retatrutide is an investigational triple-receptor agonist (GLP-1, GIP, and glucagon) that has demonstrated substantially greater weight loss than Wegovy in clinical trials.

• Phase 2 (NEJM 2023): Up to 24.2% weight loss at 48 weeks with the 12 mg dose, versus Wegovy’s 14.9% at 68 weeks
• Phase 3 TRIUMPH-4 (December 2025): 28.7% weight loss at 68 weeks in participants with obesity and knee osteoarthritis, with a 75.8% reduction in WOMAC pain scores

The triple-agonist mechanism works through three complementary pathways: GLP-1 receptor agonist activity, GIP receptor activity, and glucagon receptor activity. In trial settings, that multi-pathway approach has been associated with larger mean weight-loss percentages than single-agonist semaglutide 2.4 mg. Wegovy’s STEP 1 result was approximately 15%, while retatrutide’s reported Phase 2 and TRIUMPH-4 figures were materially higher.

Retatrutide is not approved for clinical use anywhere. Seven additional TRIUMPH Phase 3 trials are expected to report through 2026, evaluating efficacy in obesity, type 2 diabetes, sleep apnoea, chronic low back pain, cardiovascular/renal outcomes, and MASLD. For a comprehensive comparison of next-generation obesity compounds, see our retatrutide vs tirzepatide vs CagriSema analysis.